Zai Lab Executive and Leadership Team

Kari Lee, the Deputy Chief Financial Officer at Zai Lab, directs financial operations and reporting. Overseeing fiscal strategy, Kari Lee ensures robust financial planning and analysis to support the company's growth in oncology and autoimmune disease research. This leadership position involves managing budgets, optimizing resource allocation, and maintaining compliance with financial regulations. By implementing effective financial controls, Kari Lee contributes directly to Zai Lab's operational stability and its mission to bring innovative therapies to market. The role demands meticulous attention to detail and a deep understanding of the pharmaceutical industry's financial landscape, ensuring Zai Lab's long-term sustainability and capacity for continued drug discovery and development.

Xiaoxi Wang, the Deputy Chief Financial Officer at Zai Lab, manages critical aspects of the company's financial architecture. Focusing on capital management and investment strategy, Xiaoxi Wang supports Zai Lab's expansion in bio-pharmaceuticals. This role involves detailed financial modeling, risk assessment, and ensuring the efficient deployment of capital for research and development initiatives. By collaborating with other finance leaders, Xiaoxi Wang strengthens the company's financial resilience and its ability to fund groundbreaking work in oncology and autoimmune diseases. The position requires a strategic financial perspective to navigate the complexities of drug discovery and commercialization, ultimately driving Zai Lab's mission forward.

Diana Liu, the Deputy Chief Financial Officer at Zai Lab, oversees key financial planning and treasury functions. Driving financial discipline, Diana Liu ensures that Zai Lab's resources are strategically allocated to advance its pipeline of oncology and autoimmune disease treatments. This leadership capacity includes managing cash flow, overseeing accounting practices, and supporting investor relations with accurate financial data. By maintaining rigorous financial oversight, Diana Liu reinforces Zai Lab's commitment to operational excellence and its capacity for sustained innovation in drug discovery. The role is pivotal in ensuring the company's financial health and its ability to achieve its ambitious therapeutic goals.

Joshua Smiley, the President & Chief Operating Officer at Zai Lab, directs the company's day-to-day operations and strategic execution. Overseeing all functional departments, Joshua Smiley ensures seamless integration of drug discovery, development, and commercialization efforts. This leadership role involves optimizing operational efficiency, managing supply chains, and fostering a culture of innovation across the organization. By driving operational excellence, Joshua Smiley directly supports Zai Lab's mission to deliver novel therapies for oncology and autoimmune diseases. The position requires a comprehensive understanding of the bio-pharmaceutical landscape to effectively scale operations and achieve critical business objectives, ensuring Zai Lab's continued impact.

William Liang, the Chief Commercial Officer & President, Greater (China) at Zai Lab, spearheads the company's commercial strategy and market expansion within China and surrounding regions. Driving market access and sales initiatives, William Liang ensures Zai Lab's innovative oncology and autoimmune disease treatments reach patients effectively. This leadership position involves building robust commercial infrastructure, forging strategic partnerships, and understanding regional market dynamics. By optimizing commercial operations, William Liang directly supports Zai Lab's mission to improve healthcare outcomes in Greater China. The role requires a deep understanding of the pharmaceutical market and a proven ability to drive revenue growth and market penetration.

Harald Reinhart, the Chief Medical Officer at Zai Lab, leads the company's clinical development strategy and execution. Guiding the advancement of Zai Lab's therapeutic pipeline, Harald Reinhart oversees clinical trials and ensures adherence to the highest medical and ethical standards in oncology and autoimmune disease research. This critical role involves translating scientific discoveries into viable patient treatments and collaborating with regulatory bodies worldwide. By championing rigorous clinical research, Harald Reinhart directly contributes to Zai Lab's objective of bringing life-changing medicines to patients. The position demands extensive medical expertise and strategic vision to navigate the complexities of drug development and regulatory approval.